Expanding Diagnostic Portfolio Immunostics has a diverse range of diagnostic solutions across oncology, women's health, infectious disease, respiratory, and toxicology, indicating opportunities to cross-sell additional tests and expand into related healthcare segments.

Recent COVID-19 Product Launch The launch of the AFIAS COVID-19 Ab test in 2020 highlights the company's ability to rapidly develop and introduce innovative testing solutions, which can be leveraged to target global infectious disease testing needs.

Acquisition & Market Entry Since Boditech Med Inc. acquired Immunostics in 2016, there is potential to explore synergies, expand product offerings, and grow sales channels within the U.S. and international markets through strategic partnerships.

Interest in Workforce Health Partnerships like that with Mountain Country Foods during the COVID-19 crisis suggest opportunities to develop point-of-care or workplace health testing solutions tailored for corporate health programs.

Technology Adoption & Visibility Immunostics utilizes multiple digital platforms and tools such as WordPress, Google Tag Manager, and Wix, which can be optimized to improve lead generation efforts and increase customer engagement in targeted healthcare markets.